文献速递消化系统肿瘤

超声双重造影QontraXt三维伪彩色定量分析对进展期胃癌术前新辅助化疗疗效评估的价值

[Value of double contrast-enhanced ultrasound QontraXt three-dimensional pseudocolor quantitative analysis to therapeutic effect evaluation of preoperative neoadjuvant chemotherapy in advanced gastric cancer patients].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

89例进展期胃癌患者接受3个疗程XELOX方案新辅助化疗后行完整病灶切除,化疗前及手术前1~2周行DCEUS QontraXt三维伪彩色定量分析。反应组52例、无反应组37例;化疗后PE、TP及ΔPE/ΔTP变化率在两组间差异有统计学意义(均P<0.05);ΔPE变化率评估疗效的AUC为0.784(P=0.004),最佳界值24%时灵敏度82.7%、特异度64.9%。

要点

  • 化疗后PE、TP及ΔPE、ΔTP变化率在反应组与无反应组间差异有统计学意义(均P<0.05)。
  • ΔPE变化率评估新辅助化疗疗效的AUC为0.784(P=0.004),优于其他参数。
  • ΔPE变化率最佳界值24%时,预测有效的灵敏度82.7%、特异度64.9%。

核心结论

  • DCEUS QontraXt三维伪彩色定量分析可能是一种新型、无创、可靠的方法,用于评估进展期胃癌患者术前新辅助化疗的疗效。

研究设计与样本

  • 89例进展期胃癌患者接受3个疗程术前新辅助化疗(XELOX:奥沙利铂+卡培他滨)后行完整病灶切除。
  • 分别于化疗前和手术前1~2周行DCEUS检查及QontraXt三维伪彩色定量分析,测量肿瘤峰值强度(PE)、达峰时间(TP)、伽马曲线尖度(β)、曲线下面积(AUC)。
  • 比较化疗前后及反应组与无反应组间造影参数及其变化率差异,并用ROC曲线评估预测准确性。

主要发现

  • 89例中反应组52例、无反应组37例;反应组黏液性癌12例、非黏液性癌40例,无反应组黏液性癌26例、非黏液性癌11例(P<0.05)。
  • 反应组化疗前PE、TP分别为(53.7±9.3)%和(14 521±2 667)ms,化疗后分别为(32.2±5.5)%和(17 235±1 898)ms;ΔPE/PE(化疗前)和ΔTP/TP(化疗前)分别为0.43±0.17和0.36±0.14。
  • 无反应组化疗前PE、TP分别为(54.4±7.2)%和(13 869±3 247)ms,化疗后分别为(45.3±6.1)%和(15 127±1 423)ms;ΔPE/PE(化疗前)和ΔTP/TP(化疗前)分别为0.24±0.20和0.22±0.12。
  • 两组间化疗后PE和TP、ΔPE/PE(化疗前)和ΔTP/TP(化疗前)差异有统计学意义(均P<0.05)。
  • ROC曲线显示ΔPE/PE(化疗前)评估胃癌新辅助化疗病理反应的价值最高(AUC=0.784,P=0.004),最佳界值24%时灵敏度82.7%、特异度64.9%。

关键数值与推荐

  • ΔPE/PE(化疗前)最佳界值为24%,预测新辅助化疗有效的灵敏度为82.7%、特异度为64.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the value of tumor perfusion parameter measured by using double contrast-enhanced ultrasound (DCEUS) QontraXt three-dimensional pseudocolor quantitative analysis to the therapeutic effect evaluation of preoperative neoadjuvant chemotherapy (NAC) in advanced gastric cancer (AGC) patients. Methods: Eighty-nine AGC patients underwent 3 cycles of preoperative NAC (XELOX) followed by complete resection of lesion. The DCEUS QontraXt three-dimensional pseudocolor was performed one or two weeks before the NAC and operation were applied, respectively. The peak enhancement (PE), time to peak (TP), sharpness of the bolus (β) and area under the enhancement curve (AUC) of primary gastric tumor were measured by QontraXt three-dimensional pseudocolor quantitative analysis. These DCEUS parameters between respond and non-respond groups before and after NAC therapy were compared. The prediction accuracy of DCEUS to the therapeutic effect evaluation of preoperative NAC was determined by the receive operating characteristic (ROC) curves. Results: Among 89 AGC patients, 52 patients responded to NAC therapy, while 37 patients resisted to NAC therapy. Twelve cases in respond group and 26 cases in non-respond group were mucinous carcinoma. Forty cases in respond group and 11 cases in non-respond group were non-mucinous carcinoma (P<0.05). In responder group, the PE and TP before NAC were (53.7±9.3)% and (14 521±2 667) ms, and (32.2±5.5)% and (17 235±1 898) ms after NAC. The ratio of changes of PE (ΔPE) and TP (ΔTP) were 0.43±0.17 and 0.36±0.14, respectively. In non-respond group, the PE and TP before NAC were (54.4±7.2)% and (13 869±3 247) ms, and (45.3±6.1)% and (15 127±1 423) ms after NAC therapy. The ratio of ΔPE and ΔTP were 0.24±0.20 and 0.22±0.12. The PE and TP after NAC, the ratio of ΔPE and ΔTP were significant different among these two groups (all of P<0.05). The ROC curves showed that the ratio of ΔPE in assessing the respond of gastric cancer patients to NAC was superior compared to other parameters (AUC=0.784, P=0.004). The optimal cut-off value of the ratio of ΔPE was 24% and its sensitivity and specificity to the therapeutic effect evaluation of NAC in gastric cancer were 82.7% and 64.9%. Conclusion: DCEUS QontraXt three-dimensional pseudocolor quantitative analysis might be a novel, noninvasive and reliable method to evaluate the therapeutic effect of preoperative NAC in AGC patients. 目的: 探讨超声双重造影(DCEUS)QontraXt三维伪彩色定量分析肿瘤组织血流灌注参数及其变化评价进展期胃癌新辅助化疗(NAC)疗效的价值。 方法: 89例进展期胃癌患者,接受3个疗程NAC(奥沙利铂+卡培他滨)联合手术治疗。分别于化疗前和手术前1~2周行DCEUS检查和QontraXt三维伪彩色定量分析,比较NAC前后、反应组和无反应组之间,峰值强度(PE)、达峰时间(TP)、伽马曲线的尖度(β)、曲线下面积(AUC)等造影参数及其变化率的差异。绘制受试者工作特征(ROC)曲线,估计诊断指标的最佳界值,计算相应的灵敏度和特异度。 结果: 89例患者中,NAC反应组52例,无反应组37例。反应组黏液性癌12例,非黏液性癌40例;无反应组黏液性癌26例,非黏液性癌11例;差异有统计学意义(P<0.05)。反应组化疗前PE、TP分别为(53.7±9.3)%和(14 521±2 667)ms,化疗后PE、TP分别为(32.2±5.5)%和(17 235±1 898)ms,ΔPE/PE(化疗前)、ΔTP/TP(化疗前)分别为0.43±0.17和0.36±0.14;无反应组化疗前PE、TP分别为(54.4±7.2)%和(13 869±3 247)ms,化疗后PE、TP分别为(45.3±6.1)%和(15 127±1 423)ms,ΔPE/PE(化疗前)、ΔTP/TP(化疗前)分别为0.24±0.20和0.22±0.12;两组间化疗后PE和TP、ΔPE/PE(化疗前)和ΔTP/TP(化疗前)差异有统计学意义(均P<0.05)。ROC曲线分析显示,ΔPE/PE(化疗前)评估胃癌NAC病理反应程度的价值最高(曲线下面积为0.784,P=0.004),当ΔPE/PE(化疗前)最佳界值为24%时,其预测胃癌NAC有效的灵敏度为82.7%,特异度为64.9%。 结论: 超声双重造影QontraXt三维伪彩色定量分析肿瘤组织血流灌注参数变化可以有效评估进展期胃癌的NAC疗效。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yan CX, Huang PT, Shentu WH, et al. [Value of double contrast-enhanced ultrasound QontraXt three-dimensional pseudocolor quantitative analysis to therapeutic effect evaluation of preoperative neoadjuvant chemotherapy in advanced gastric cancer patients]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30481939. doi:10.3760/cma.j.issn.0253-3766.2018.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。